Loading…
Senores Pharmaceuticals (SENORES)₹1,175−1.59%Pharmaceuticals
At the end of the Sep 2026 quarter, Senores Pharmaceuticals' shareholders were: promoters 45.76%, FIIs 6.03%, DIIs 10.86%, public 37.35%. Promoter holding is down 0.01 percentage points from 45.77% a quarter earlier. FII holding is up 1.74 percentage points from 4.29% a year earlier. 2.80% of promoter shares were pledged. It had 42,640 shareholders.
As of · Company filings (shareholding pattern)
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Promoters | 45.72% | 45.73% | 45.73% | 45.75% | 45.76% | 45.77% | 45.77% | 45.76% |
| FIIs | 4.26% | 4.18% | 3.67% | 4.29% | 3.36% | 3.65% | 6.64% | 6.03% |
| DIIs | 11.78% | 9.67% | 9.52% | 8.63% | 9.33% | 9.63% | 9.78% | 10.86% |
| Public | 38.24% | 40.42% | 41.08% | 41.33% | 41.55% | 40.95% | 37.81% | 37.35% |
| Promoter shares pledged | — | — | — | — | — | — | — | 2.80% |
| Number of shareholders | 49,515 | 37,651 | 36,387 | 34,915 | 34,399 | 34,124 | 36,496 | 42,640 |
| Holder | Category | Sep 2026 | Change (pp) |
|---|---|---|---|
| Swapnil Jatin Shah | Promoter | 7.67% | 0.00 |
| Ashokbhai Vijaysinh Barot | Promoter | 7.56% | +0.07 |
| Remus Pharmaceuticals Limited | Promoter | 7.12% | 0.00 |
| Renosen Pharmaceuticals Private Limited | Promoter | 5.92% | 0.00 |
| Anar Swapnil Shah | Promoter | 5.03% | 0.00 |
| Aviraj Overseas LLC | Promoter | 4.10% | 0.00 |
| Hsbc Mutual Fund - Hsbc Multi Cap Fund | DII | 2.88% | −0.57 |
| Sangeeta Mukur Barot | Promoter | 2.25% | 0.00 |
| Manoj Prakash Sanghvi | Public | 1.88% | 0.00 |
| Ratnamani Marketing Private Limited | Public | 1.83% | 0.00 |
| Bajaj Finserv Flexi Cap Fund | DII | 1.78% | New |
| Aviraj Group LLC | Promoter | 1.48% | 0.00 |
| Astorne Capital Vcc - Arven | FII | 1.37% | −0.59 |
| Aditya Birla Sun Life Insurance Company Limited | DII | 1.27% | −0.34 |
| Trustmf Small Cap Fund | DII | 1.24% | New |
| Jayanti Mishrimal Sanghvi . | Public | 1.22% | 0.00 |
| Mahindra Manulife Innovation Opportunities Fund | DII | 1.22% | New |
| Jigar Prakash Sanghvi | Public | 1.20% | 0.00 |
| Jitendra Babulal Sanghvi | Promoter | 1.07% | 0.00 |
| Espee Therapeutics LLP | Promoter | 1.06% | 0.00 |
| Prakash Mishrimal Sanghvi | Public | 1.04% | 0.00 |
| Mukur Yogeshkumar Barot | Promoter | 0.98% | 0.00 |
| Shantaben Babulal Sanghvi | Promoter | 0.72% | 0.00 |
| Dhananjay Ashokkumar Barot | Promoter | 0.61% | −0.07 |
| Hemant Ishwarlal Modi | Promoter | 0.13% | 0.00 |
Promoters held 45.76% of Senores Pharmaceuticals at the end of the Sep 2026 quarter, up 0.01 percentage points from 45.75% a year earlier.
In the Sep 2026 quarter, foreign institutional investors (FIIs) held 6.03% (down 0.61 percentage points from 6.64% a quarter earlier) and domestic institutions (DIIs) held 10.86% (up 1.08 percentage points from 9.78% a quarter earlier).
Yes. 2.80% of promoter shares were pledged at the end of the Sep 2026 quarter.
Senores Pharmaceuticals had 42,640 shareholders at the end of the Sep 2026 quarter, against 34,915 a year earlier.
Hsbc Mutual Fund - Hsbc Multi Cap Fund (DII) held 2.88% at the end of the Sep 2026 quarter, the largest named holding outside the promoter group.